Kevin Hickman - Ryman Healthcare Director
| RYHTY Stock | USD 12.86 0.19 1.46% |
Director
Mr. Kevin J. Hickman is an NonExecutive Independent Director of the company. He cofounded Ryman Healthcare. He held the role of managing director in a joint capacity from 1984 and in a sole capacity from 2002 to 2006. Kevin has considerable experience as a director and manager of a diverse range of businesses in the private sector, including the retail, telecommunications and manufacturing sectors. Kevins family trust remains a signifi cant shareholder in Ryman Healthcare. In 2016 Kevin was made an Offi cer of the New Zealand Order of Merit for his services to sport and aged care. since 2006.
| Tenure | 18 years |
| Phone | 64 3 366 4069 |
| Web | https://www.rymanhealthcare.co.nz |
Ryman Healthcare Management Efficiency
Ryman Healthcare's management efficiency ratios could be used to measure how well Ryman Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Antoinette Hubenette | The Ensign Group | 67 | |
| Sui Yan | Concord Medical Services | N/A | |
| Emil Hassan | National HealthCare | 72 | |
| Lawrence Tucker | National HealthCare | 75 | |
| Joan Herman | Encompass Health Corp | 67 | |
| Chris Gordon | Acadia Healthcare | 44 | |
| Barry Smith | The Ensign Group | 64 | |
| Lee Daniels | The Ensign Group | 61 | |
| Vicky Gregg | Acadia Healthcare | 63 | |
| Ernest Burgess | National HealthCare | 79 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| Ziad Mirza | InnovAge Holding Corp | 53 | |
| Zhe Yin | Concord Medical Services | N/A | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Thomas Scully | Select Medical Holdings | 63 | |
| Malene Davis | The Ensign Group | 55 | |
| Daniel Thomas | Select Medical Holdings | 62 | |
| Wade Miquelon | Acadia Healthcare | 53 | |
| Russell Carson | Select Medical Holdings | 77 | |
| Leopold Swergold | Select Medical Holdings | 77 | |
| Marilyn Tavenner | Select Medical Holdings | 69 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | -7.0E-4 |
Ryman Healthcare Leadership Team
Elected by the shareholders, the Ryman Healthcare's board of directors comprises two types of representatives: Ryman Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ryman. The board's role is to monitor Ryman Healthcare's management team and ensure that shareholders' interests are well served. Ryman Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ryman Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claire Higgins, Non-Executive Independent Director | ||
| Anthony Leighs, Independent Director | ||
| Cameron Holland, Chief Australia | ||
| Richard Umbers, Group Exec | ||
| Gordon MacLeod, CFO, Deputy Chief Executive and Company Secretary | ||
| Kevin Hickman, Co-Founder, Director and Member of Remuneration and Nominations Committee | ||
| Taylor Allison, Design Manager | ||
| Michelle Perkins, IR Contact Officer | ||
| Simon Challies, CEO, Managing Director, Executive Director | ||
| Tom Brownrigg, Construction Manager | ||
| Jo Appleyard, Independent Non-Executive Director | ||
| Jenn Poskitt, Marketing Manager | ||
| Philip Mealings, Property and Purchasing Manager | ||
| George Savvides, Independent Director | ||
| Douglas McKay, Independent Director | ||
| Cheyne Chalmers, Chief Zealand | ||
| Debbie McClure, Group Sales Manager | ||
| Warren Bell, Independent Non-Executive Director | ||
| David Bennett, Group Officer | ||
| Deborah Marris, G Sec | ||
| Marsha Cadman, Chief Officer | ||
| Rick Davies, Chief Officer | ||
| Andrew Mitchell, Development Manager | ||
| David Kerr, Independent Non-Executive Chairman of the Board | ||
| Geoffrey Cumming, Director | ||
| MaryAnne Stone, Chief Officer | ||
| David King, Corporate Affairs Manager | ||
| Chris BE, Chief Officer | ||
| Barbara ReynenRose, Operations & Clinical Services Manager | ||
| Nicole Forster, Group Shared Services Manager |
Ryman Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ryman Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | -7.0E-4 | |||
| Profit Margin | 1.13 % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.91 B | |||
| Shares Outstanding | 100 M | |||
| Price To Earning | 10.13 X | |||
| Price To Book | 0.85 X | |||
| Price To Sales | 3.74 X | |||
| Revenue | 503.76 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ryman Healthcare in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ryman Healthcare's short interest history, or implied volatility extrapolated from Ryman Healthcare options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ryman Healthcare Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Ryman Pink Sheet analysis
When running Ryman Healthcare's price analysis, check to measure Ryman Healthcare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ryman Healthcare is operating at the current time. Most of Ryman Healthcare's value examination focuses on studying past and present price action to predict the probability of Ryman Healthcare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ryman Healthcare's price. Additionally, you may evaluate how the addition of Ryman Healthcare to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |